RxDoctor Payments Data

Robert Harris, MD

Internal Medicine · Dallas, TXNPI 1174566053

Payments from drug & device makers

$616in general payments, 2019–2025

Across 21 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$150
  • Novartis$124
  • Lilly USA, LLC$54
  • Abbott$44
  • Amgen$42
  • E.r. Squibb & Sons, L.L.C.$40
  • plus $162 from 7 others

What the payments were for

  • Consulting fees$15024%
  • Food & beverage$46676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$616 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$66,916
Medicare patients
430
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$39,808
OzempicSemaglutide25$24,444
MounjaroTirzepatide20$21,335
TrulicityDulaglutide13$18,887
CreonLipase/Protease/Amylase11$13,301
Rosuvastatin Calcium356$4,685
Atorvastatin Calcium503$4,182
Levothyroxine Sodium226$3,180
SynthroidLevothyroxine Sodium30$2,685
Metoprolol Succinate150$2,178
Lisinopril231$2,020
Tamsulosin Hcl86$1,923
Amlodipine Besylate265$1,477
Metformin Hcl163$1,430
Albuterol Sulfate HfaAlbuterol Sulfate49$1,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$54$40,22233 claims
PfizerEliquis$40$39,80861 claims
Novo NordiskOzempic$19$24,44425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →